Simian Vaccine Evaluation Units (SVEUs) 2020

IDIQ

Description

Provide support to maintain and acquire nonhuman primates, and the scientific and technical expertise necessary to conduct studies in nonhuman primates with the objective of providing information that will lead to the development of a human vaccine that can provide broadly reactive and long-lasting protective immunity against HIV infection.

Overview

Ceiling

$66,355,351

Primary Sponsoring Agency

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Primary PSC

AN81 - R&D- Medical: Aids Research (Basic Research)

Primary Set Aside

None

Extent Competed

Full And Open Competition

Related Opportunity

Simian Vaccine Evaluation Units (SVEUs) (NIAID-DAIDS-NIHAI201800011)

Predecessor

Simian Vaccine Evaluation Units (SVEUs) 2013

Simian Vaccine Evaluation Units (SVEUs) 2020 awarded by National Institute of Allergy and Infectious Diseases (NIAID) in April 2020 accepts orders through March 2027. The IDIQ has a reported ceiling of $66,355,351, and as of today, $42,440,850 has been obligated through the vehicle with a total reported backlog of $4,439,041. The IDIQ was awarded full & open and has a primary NAICS code of 541715.

Award Hierarchy

Vehicle

Simian Vaccine Evaluation Units (SVEUs) 2020

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

4/1/20

Start Date

3/31/27

Ordering Period End Date

79.0% Complete

Task Order Obligations and Backlog

$42.4M

Total Obligated

$42.4M

Current Award

$46.9M

Potential Award

91% Funded

$0.0

Funded Backlog

$4.4M

Total Backlog

Vehicle Award Share

Contractors with greatest percentage of obligations for Simian Vaccine Evaluation Units (SVEUs) 2020

Vehicle Award Share

Federal Award Analysis